Deerfield Management’s Black Diamond Therapeutics BDTX Stock Holding History

Deerfield Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-930,447	Closed	-$2.67M	–	224
2023 Q3	$2.67M	Sell	930,447 -869,553	-48%	-$3.2M	0.06%	71
2023 Q2	$9.09M	Buy	+1,800,000	New	+$3.68M	0.19%	74
2021 Q4	–	Sell	-760,128	Closed	-$6.43M	–	131
2021 Q3	$6.43M	Sell	760,128 -287,471	-27%	-$2.84M	0.13%	107
2021 Q2	$12.8M	Hold	1,047,599	–	–	0.23%	103
2021 Q1	$25.4M	Buy	1,047,599 +245,088	+31%	+$6.61M	0.53%	65
2020 Q4	$25.7M	Hold	802,511	–	–	0.51%	64
2020 Q3	$24.3M	Buy	802,511 +266,510	+50%	+$8.11M	0.59%	58
2020 Q2	$22.6M	Hold	536,001	–	–	0.66%	47
2020 Q1	$13.4M	Buy	+536,001	New	+$16.3M	0.42%	63

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deerfield Management's BDTX Position: Q4 2023 in Review

Deerfield Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2023, closing a stake of 930,447 shares — an estimated $2.67M sold.

Deerfield Management first reported a position in BDTX in Q1 2020 and held it in 9 quarters. The position peaked at $25.7M in Q4 2020. 76 funds tracked by Wall St. Rank hold BDTX as of Q4 2023.

Deerfield Management reported no remaining Black Diamond Therapeutics position as of Q4 2023 after selling out during the quarter.
Deerfield Management sold 930,447 Black Diamond Therapeutics shares in Q4 2023, an estimated $2.67M.
Deerfield Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 9 quarters.
Deerfield Management's Black Diamond Therapeutics position peaked at $25.7M in Q4 2020.
76 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2023.

Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.